Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3235-3244

  Qin, Jun ^a   Yang, Bo ^a   Xu, Bao Qin ^b   Smithc, Amber ^c   Xu, Liang ^c   Yuan, Jian Lin ^a   Li, Ling ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

ccRCC; CD44s; Prognosis; pSTAT3; Survival

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904318442     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jeong BJ, Liang ZL, Huang SM, Lim JS, Kim JM and Lee HJ. CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy. Exp Ther Med 2012; 3: 811-817.
2. Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013; 5: 338-353.
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
4. Lim SD, Young AN, Paner GP and Amin MB. Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch 2008; 452: 49-55.
5. Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B and Chouaib S. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer 2014; 110: 1778-1784.
6. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ and Powles T. Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. Eur Urol 2014; 65: 766-777.
7. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
8. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
9. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS and Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4: e6816.
10. Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, Lawrence TS and Xu L. Antibody Against CD44s Inhibits Pancreatic Tumor Initiation and Postradiation Recurrence in Mice. Gastroenterology 2014; 16: 1108-1118.
11. Matuschek C, Lehnhardt M, Gerber PA, Poremba C, Hamilton J, Lammering G, Orth K, Budach W, Bojar H, Bolke E and Peiper M. Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study. Eur J Med Res 2014; 19: 6.
12. Liang YM, Li XH, Li WM and Lu YY. Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors. World J Gastroenterol 2012; 18: 1664-1671.
13. Chen J, Zhou J, Lu J, Xiong H, Shi X and Gong L. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 2014; 14: 15.
14. Tei H, Miyake H, Harada KI and Fujisawa M. Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: Effect on prognostic outcomes following radical prostatectomy. Urol Oncol 2014; 32: 694-700.
15. Zhang J, Chang B and Liu J. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis. Hum Pathol 2013; 44: 1882-1889.
16. Kroeze SG, Bijenhof AM, Bosch JL and Jans JJ. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark 2010; 7: 261-268.
17. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF and Holzbeierlein J. Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 2007; 131: 261-267.
18. Costa WH, Rocha RM, Cunha IW, Guimaraes GC and Zequi Sde C. Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance. Int Braz J Urol 2012; 38: 456-465.
19. Bourguignon LY, Earle C, Wong G, Spevak CC and Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012; 31: 149-160.
20. Bourguignon LY, Peyrollier K, Xia W and Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multi drug efflux in breast and ovarian tumor cells. J Biol Chem 2008; 283: 17635-17651.
21. Li N, Grivennikov SI and Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer cell 2011; 19: 429-431.
22. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA and Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
23. Johnston PA and Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv 2011; 11: 18-26.
24. Guo C, Yang G, Khun K, Kong X, Levy D, Lee P and Melamed J. Activation of Stat3 in renal tumors. Am J Transl Res 2009; 1: 283-290.
25. Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS and Xu L. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res 2013; 19: 6703-6715.
26. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS and Xu L. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1217-1225.
27. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y and Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45: 860-867.
28. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H and Baba H. CD44s Regulates the TGF-beta-Mediated Mesenchymal Phenotype and Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Res 2012; 72: 3414-3423.
29. Okabe H, Ishimoto T, Mima K, Nakagawa S, Hayashi H, Kuroki H, Imai K, Nitta H, Saito S, Hashimoto D, Chikamoto A, Ishiko T, Watanabe M, Nagano O, Beppu T, Saya H and Baba H. CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br J Cancer 2014; 110: 958-966.
30. Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS and Lin J. Evaluation of STAT3 Signaling in ALDH+ and ALDH+/CD44+/CD24- Subpopulations of Breast Cancer Cells. PLoS One 2013; 8: e82821.
31. Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi J, Ding Y and Wang S. STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res 2012; 26: 325-335.
32. So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, Liu F and Suh N. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 2013; 8: e54020.
33. Lee JL, Wang MJ and Chen JY. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. J Cell Biol 2009; 185: 949-957.
34. Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C, Chomienne C and Smadja-Joffe F. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 1999; 5: 669-676.
35. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J and Lin J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445-2454.